以色列Compugen
Compugen 成立于1993年，其宗旨是通过计算机技术同生物学和医学的结合，发现和开发新药。此公司的优势是具有雄厚的多学科基础，其团队由数学家、计算机学家、物理学家、化学家和分子生物学家组成，主要业务是用计算机技术分析和解释生物学现象和数据，加速基因组学、蛋白质组学和其他生物学数据的处理，研究基因组学、功能基因组学和蛋白质组学，研发针对癌症、免疫缺陷和神经病的生物技术药物、药物靶点和诊断标记。

Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The Company’s increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery – field after field – of numerous therapeutic and diagnostic product candidates. These discovery platforms are based on the Company’s decade-long focus on the predictive understanding of important biological phenomena at the molecular level. Compugen’s current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate – Evogene Ltd. (TASE: EVGN.TA) – to utilize the Company’s in silico predictive discovery capabilities in the agricultural biotechnology field. 

Compugen has been publicly traded on Nasdaq (NASDAQ: CGEN) since August 2000 and on the Tel Aviv Stock Exchange since January 2002.